← Back
Data updated: Mar 10, 2026
NOVELGENIX THERAPS
Immunology
NOVELGENIX THERAPS is a generic drug manufacturer focused on Immunology.
2018
Since
1
Drugs
-
Trials
21
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
NAPROXEN SODIUM 2026-01-24
Labeling
NAPROXEN SODIUM 2026-01-24
Labeling
NAPROXEN SODIUM 2026-01-24
Labeling
NAPROXEN SODIUM 2026-01-15
Labeling
NAPROXEN SODIUM 2025-09-16
Labeling
NAPROXEN SODIUM 2025-09-16
Labeling
NAPROXEN SODIUM 2025-09-16
Labeling
NAPROXEN SODIUM 2025-09-16
Labeling
NAPROXEN SODIUM 2025-08-28
Labeling
NAPROXEN SODIUM 2025-08-28
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Immunology 100%
1 drugs
Pipeline Strength Pro
Loading...
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2018-11-16
- Latest
- 2018-11-16
- Applications
- 1